Published in J Clin Bioinforma on December 28, 2012
Circulating miR-200c and miR-141 and outcomes in patients with breast cancer. BMC Cancer (2015) 0.86
The potential of microRNAs in personalized medicine against cancers. Biomed Res Int (2014) 0.84
Rs3842530 Polymorphism in MicroRNA-205 Host Gene in Lung and Breast Cancer Patients. Med Sci Monit (2016) 0.79
Robust Selection Algorithm (RSA) for Multi-Omic Biomarker Discovery; Integration with Functional Network Analysis to Identify miRNA Regulated Pathways in Multiple Cancers. PLoS One (2015) 0.79
miR-200c dampens cancer cell migration via regulation of protein kinase A subunits. Oncotarget (2015) 0.78
Cis-acting elements in its 3' UTR mediate post-transcriptional regulation of KRAS. Oncotarget (2016) 0.75
Web-based tools for microRNAs involved in human cancer. Oncol Lett (2016) 0.75
YM500v3: a database for small RNA sequencing in human cancer research. Nucleic Acids Res (2016) 0.75
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell (1993) 64.62
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med (2005) 26.02
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature (2007) 21.53
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
MicroRNAs in plants. Genes Dev (2002) 20.12
Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature (2000) 19.15
Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res (2003) 17.13
Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet (2007) 15.46
Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 14.37
Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA (2005) 14.14
Retracted A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell (2009) 10.51
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A (2007) 9.82
Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell (2007) 9.51
microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A (2006) 8.24
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat (2009) 7.91
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet (2006) 7.53
A microRNA signature of hypoxia. Mol Cell Biol (2006) 7.24
Cell-type-specific signatures of microRNAs on target mRNA expression. Proc Natl Acad Sci U S A (2006) 7.11
mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene (2007) 7.02
Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle (2007) 7.00
MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem (2007) 6.88
p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol (2007) 6.87
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol (2010) 6.67
Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene (2006) 6.61
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol (2007) 6.41
Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res (2007) 5.62
MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell (2008) 5.34
An E2F/miR-20a autoregulatory feedback loop. J Biol Chem (2006) 5.20
Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood (2007) 5.14
miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem (2007) 5.02
Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem (2006) 4.57
Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci (2005) 4.55
MicroRNAs in cancer. Annu Rev Pathol (2009) 4.47
An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A (2007) 3.54
Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol (2008) 3.18
An optimized isolation and labeling platform for accurate microRNA expression profiling. RNA (2005) 3.12
MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res (2009) 3.05
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol (2008) 3.02
Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle (2007) 2.78
MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer (2008) 2.76
Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer (2012) 2.74
Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res (2007) 2.65
Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol (2010) 2.40
EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol (2008) 2.29
MicroRNA-143 and -145 in colon cancer. DNA Cell Biol (2007) 2.24
MicroRNA genes are frequently located near mouse cancer susceptibility loci. Proc Natl Acad Sci U S A (2007) 1.90
A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One (2011) 1.87
Global microRNA profiles in cervical squamous cell carcinoma depend on Drosha expression levels. J Pathol (2007) 1.74
Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood (2009) 1.45
The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer (2011) 1.35
Up-regulation of microRNA-21 correlates with lower kidney cancer survival. PLoS One (2012) 1.26
Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. Oncogene (2010) 1.26
Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer. Genes Chromosomes Cancer (2011) 1.24
CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res (2006) 6.35
NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem (2003) 3.98
Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat (2009) 2.85
Obesity potentiates the growth and dissemination of pancreatic cancer. Surgery (2009) 2.64
Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res (2009) 2.27
FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. Clin Cancer Res (2007) 2.22
SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype. BMC Cancer (2010) 1.56
Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res (2004) 1.53
ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer. Cancer Biol Ther (2010) 1.44
Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res (2009) 1.39
The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol Cancer Ther (2005) 1.33
Identity profiling of cell surface markers by multiplex gold nanorod probes. Nano Lett (2007) 1.30
Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Res (2007) 1.29
PROGgene: gene expression based survival analysis web application for multiple cancers. J Clin Bioinforma (2013) 1.28
Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis (2008) 1.24
Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin Cancer Res (2006) 1.23
AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer. Mol Cell Biol (2008) 1.21
Breast-cancer stem cells-beyond semantics. Lancet Oncol (2012) 1.21
FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res Treat (2011) 1.17
Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover. Carcinogenesis (2007) 1.16
The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1alpha/CXCL12. Carcinogenesis (2005) 1.16
Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. Mol Cancer Ther (2005) 1.16
The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells. J Biol Chem (2006) 1.13
Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs (2004) 1.09
Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation. Mol Endocrinol (2004) 1.09
Role of AKT isotypes in breast cancer. J Pathol (2013) 1.07
High-level expression of forkhead-box protein A1 in metastatic prostate cancer. Histopathology (2011) 1.07
PROGgeneV2: enhancements on the existing database. BMC Cancer (2014) 1.07
Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Breast Cancer Res (2011) 1.05
HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression. Cancer Res (2013) 1.05
Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells. Oncogene (2002) 1.03
ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer. Cancer Res (2013) 1.00
NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Lett (2009) 0.99
Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications. Am J Pathol (2010) 0.99
Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Mol Cancer Ther (2007) 0.97
Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse. Cancer Nanotechnol (2012) 0.96
Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. Mod Pathol (2009) 0.96
The macrophage inhibitory cytokine integrates AKT/PKB and MAP kinase signaling pathways in breast cancer cells. Carcinogenesis (2005) 0.95
Loss of ERα and FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model. Oncol Rep (2010) 0.95
Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet. Cancer Res (2010) 0.94
Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer. Am J Pathol (2003) 0.92
Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-negative breast cancer cells in brain. J Pathol (2014) 0.92
A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-κB and generating reactive oxygen species. Int J Cancer (2011) 0.91
Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity. Sci Rep (2013) 0.90
2-methoxyestradiol inhibits the anaphase-promoting complex and protein translation in human breast cancer cells. Cancer Res (2007) 0.89
A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappaB and generating reactive oxygen species. Prostate (2010) 0.88
Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis. J Med Chem (2011) 0.85
Interplay between estrogen receptor and AKT in estradiol-induced alternative splicing. BMC Med Genomics (2013) 0.85
Antimyeloma effects of a sesquiterpene lactone parthenolide. Clin Cancer Res (2008) 0.84
Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. Prostate (2006) 0.84
Radiation resistance in breast cancer: are CD44+/CD24-/proteosome low/PKH26+ cells to blame? Breast Cancer Res (2010) 0.83
TFAP2C expression in breast cancer: correlation with overall survival beyond 10 years of initial diagnosis. Breast Cancer Res Treat (2015) 0.81
Negative regulation of MHC class II gene expression by CXCR4. Exp Hematol (2006) 0.81
Parthenolide sensitizes cells to X-ray-induced cell killing through inhibition of NF-kappaB and split-dose repair. Radiat Res (2007) 0.80
Striatin-3 gamma inhibits estrogen receptor activity by recruiting a protein phosphatase. J Mol Endocrinol (2008) 0.80
Effect of celecoxib and novel agent LC-1 in a hamster model of lung cancer. J Surg Res (2007) 0.79
MOZ and MOZ-CBP cooperate with NF-kappaB to activate transcription from NF-kappaB-dependent promoters. Exp Hematol (2007) 0.79
Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel. Anticancer Res (2005) 0.78
A large, consistent plasma proteomics data set from prospectively collected breast cancer patient and healthy volunteer samples. J Transl Med (2011) 0.77
Biomarkers for breast cancer stem cells: the challenges ahead. Biomark Med (2011) 0.76